2013


To access this material please log in or register

Register Authorize
2013/№4

Report of the Expert Council “Role of Omacor in current cardiology”

Arutyunov G. P., Rupp H., Karpov Yu. A., Lopatin Yu. M., Moiseev V. S.

Keywords: treatment, omega-3 fatty acids, cardiovascular pathology

DOI: 10.18087/rhj.2013.4.1866

  1. De Caterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med. 2011;364 (25):2439–2450.
  2. Leaf A, Xiao YF, Kang JX, Billman GE. Membrane effects of the n-3 fish oil fatty acids, which prevent fatal ventricular arrhythmias. J Membr Biol. 2005;206 (2):129–139.
  3. Oh DY, Talukdar S, Bae EJ et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensiti­zing effects. Cell. 2010;142 (5):687–698.
  4. Calder P. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol. 2013;75 (3):645–662.
  5. Cawood AL, Ding R, Napper FL et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorpo­rated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212 (1):252–259.
  6. Rupp H, Rupp TP, Alter P, Maisch B. Inverse shift in serum polyunsaturated and monounsaturated fatty acids is associated with adverse dilatation of the heart. Heart. 2010;96 (8):595–598.
  7. Rupp H, Rupp TP, Alter P, Maisch B. Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsa­turated fatty acids by structural heart disease resulting in «HUFA deficiency». Can J Physiol Pharmacol. 2012;90 (1):55–73.
  8. Albert CM, Campos H, Stamfer MJ et al. Blood levels of long chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346 (15):1113–1118.
  9. Nodari S, Triggiani M, Campia U et al. Effects of n-3 polyunsatura­ted fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2011;57 (7):870–879.
  10. Macchia A, Levantesi G, Franzosi MG et al, for the GISSI-Prevenzione Investigators. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail. 2005;7 (5):904–909.
  11. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354 (9177):447–455.
  12. Marchioli R, Barzi F, Bomba E. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) – Prevenzione. Circulation. 2002;105 (16):1897–1903.
  13. Tavazzi L, Maggioni AP, Marchioli R. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372 (9645):1223–1230.
  14. The ORIGIN trial investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N. N Engl J Med. 2012;367 (4):309–318.
  15. Mozaffarian D, Marchioli R, Macchia A et al. Fish oil and post­operative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA. 2012;308 (19):2001–2011.
  16. Rauch B, Schiele R. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122 (21):2152–2159.
  17. Bianconi L, Calò L, Mennuni M et al. n-3 Polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study. Europace. 2011;13 (2):174–181.
  18. Nodari S, Triggiani M, Campia U et al. n-3 Polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: A prospective, randomized study. Circulation. 2011;124 (10):1100–1106.
  19. Моисеев С. В. n-3 Полиненасыщенные жирные кислоты: о чем свидетельствуют результаты последних мета-анализов? Клин. фармакол. тер. 2013;22 (1):23–28.
  20. Rizos EC, Ntzani EE, Bika E et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308 (10):1024–1033.
  21. Xin W, Wei W, Li X. Effects of fish oil supplementation on cardiacfunction in chronic heart failure. A meta-analysis of randomised controlled trials. Heart. 2012;98 (22):1620–1625.
  22. Gissi-Hf Investigators. Effect of rosuvastatin in patients with chro­nic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372 (9645):1231–1239.
  23. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin i in older patients with systolic heart failure. N Engl J Med. 2007;357 (22):2248–2261.
  24. Poole CD, Halcox JP, Jenkins-Jones S et al. Omega-3 fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: A retrospective, matched-cohort study. Clin Ther. 2013;35 (1):40–51
Arutyunov G. P., Rupp H., Karpov Yu. A. et al. Report of the Expert Council “Role of Omacor in current cardiology”. Russian Heart Journal. 2013;12(4):259-264

To access this material please log in or register

Register Authorize
Ru En